NEWTOWN, PA — Helius Medical Technologies, Inc. (Nasdaq: HSDT) announced this week that it has secured continued listing on the Nasdaq Capital Market after successfully meeting key financial requirements.
On July 7, the company received formal confirmation from the Nasdaq Hearings Panel that it is now in compliance with Nasdaq Listing Rule 5550(b)(1), which sets minimum stockholders’ equity thresholds for continued listing. This follows an earlier notification on June 3, in which Nasdaq confirmed that Helius had regained compliance with the minimum bid price requirement under Nasdaq Marketplace Rule 5550(a)(2).
With these developments, Helius Medical is now fully compliant with all Nasdaq continued listing standards, a significant milestone that reinforces its financial stability and operational progress.
Despite this achievement, the company will remain under a Mandatory Panel Monitor for one year, in line with Nasdaq’s oversight policies outlined in Listing Rule 5815(d)(4)(B). This monitoring period is intended to ensure ongoing adherence to listing criteria.
Helius Medical Technologies, known for its focus on neurostimulation therapies, faced previous challenges maintaining its Nasdaq listing due to market price volatility and equity concerns. The company’s successful compliance efforts represent a critical step in restoring investor confidence and sustaining its market presence.
As Helius looks ahead, maintaining its listing supports its broader strategic goals, including advancing its clinical programs and strengthening its financial position to drive long-term growth.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.